Novel nonsteroidal topical therapies for pediatric atopic dermatitis: a systematic review and network meta-analysis of randomized controlled trials.

The network was largely centered on vehicle, with only one active-comparator trial.

Most active regimens improved IGA-TS versus vehicle, except tapinarof 0.5% once daily.

For EASI-75, five of ten evaluated active regimens showed significant benefit, while all six regimens evaluated for EASI-90 were superior to vehicle.

Delgocitinib 0.5% twice daily ranked highest for IGA-TS and EASI-75, whereas difamilast 1% twice daily ranked highest for EASI-90.